Cissy Kityo
ID: UNCST-2021-R013663
|
Platform Assessing Regimens And Durations In a Global Multisite consortium for TB. A Seamless Phase 2B/2C Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary Tuberculosis
REFNo: HS3044ES
Phase 2C: Amongst regimens selected for progression from phase 2B, to further evaluate the safety profile and to identify the optimal treatment duration (between 8 and 16 weeks) based on unfavourable outcome to support advancement to future Phase 3 trials.,Phase 2B: To identify regimens with acceptable safety profile that have the greatest potential, based on assessment of quantitative sputum liquid culture and treatment failure/relapse to progress to investigation of optimal treatment duration in Phase 2C.,To identify novel drug regimen(s) with acceptable safety profile, non-inferior efficacy and shortened treatment duration compared to the standard-of-care 24-week HRZE regimen that could be used to treat people with rifampicin susceptible and rifampicin resistant TB.,
|
Kampala, Kampala
Wakiso, Kampala
Mukono, Kampala
Mpigi, Mpigi
|
Uganda |
2023-12-01 17:56:07 |
2026-12-01 |
Up to 2500 overall will be enrolled, 700 in phase 2B and 1800 in phase 2C. An estimate of 165 patients in total for Uganda sites (60 in phase 2B and 105 in phase 2C) and about 30 patients for JCRC Lubowa in phase 2B and 55 patients in phase 2C. |
Adults ≥18 years with newly diagnosed pulmonary TB will be enrolled |
University College London |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Achilles Katamba
ID: UNCST-2019-R000540
|
Peer-led Implementation of TB-HIV Education and Adherence Counselling in Uganda
REFNo: HS4801ES
To evaluate the implementation fidelity and context of a peer-navigation strategy for TB-EC to improve TB treatment and ART outcomes, To determine the feasibility, acceptability, and appropriateness of a peer-navigation strategy for TB-EC and explore the social-behavioral mechanisms for improving adherence and clinical outcomes. ,To evaluate the implementation of a peer-navigation strategy for TB-EC to improve TB treatment completion and ART retention. , To evaluate the effectiveness and implementation of a novel, peer-led TB education and counseling strategy to improve outcomes among persons with tuberculosis (TB) with and without HIV/AIDS and assess the social-behavioral mechanisms underlying the observed treatment effects. ,
|
Kampala,
Kampala,
Kampala,
Kampala,
Jinja, Wanyange
Jinja,
Buikwe,
Iganga,
Kiboga,
Mityana,
Butambala,
Wakiso,
Wakiso,
Kayunga,
Kampala,
Kamuli,
Luweero,
Lyantonde,
Mukono,
|
Uganda |
2024-09-10 10:03:57 |
2027-09-10 |
1920 index cases |
Study population in Aim 1:
Our target population is adults (age ≥18) starting treatment for TB/TB-HIV in public, private, and private not-for-profit primary care clinics in Uganda. Targeting this population will allow us to assess the impact of the TB-EC on TB and ART treatment adherence and outcomes across a diverse population.
Study population Aim 2:
For the pilot study to test Aim 2 instruments, we will enroll adults (age ≥18) undergoing evaluation for TB and on TB treatment in primary care clinics.
All participants in Aim 1 of the study will participate in the Aim 2 of the study. We administer social and behavioral scales through the surveys that will be conducted in Aim 2.
Study population in Aim 3:
Aim 3 participants will include a subgroup of individuals enrolled in the Aim 1 trial, their peer navigators, and healthcare workers at study sites.
|
National Institute of health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Hannah Kibuuka
ID: UNCST-2020-R014355
|
PROTECT-APT 1 _ Master Protocol for Early Treatment and Post-Exposure Prophylaxis of COVID-19 Adaptive Platform Trial V3.0 dated 02 June 2023 and Appendix C entitled “A phase 2 safety and efficacy study of upamostat for early outpatient treatment of COVID-19” V3.0 dated 01 June, 2023
REFNo: HS3116ES
To determine if early treatment with upamostat can shorten time to sustained symptom alleviation or resolution in participants infected with SARS-CoV-2.
|
Kabarole, Baza
|
Uganda |
2024-06-24 0:12:16 |
2027-06-24 |
40 |
Adult male and female participants aged 18 years and above |
FHI Clinical |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Juliet Babirye Ndimwibo
ID:
|
TREAT INTERACT: Implementing a user involved education- and health system interactive task-shifting approach for child mental health promotion in Uganda
REFNo: HS3144ES
Based on findings from objectives 1-2, develop implementation advice to guide policymakers in school-based child and adolescent mental health (CAMH) management, integration with the health system, and how to implement and sustain large-scale evidence-informed CAMH interventions to contribute towards achieving universal mental health coverage. ,Develop, implement and evaluate an intersectoral supervision, referral and communication model between the health and education sector.,Implement the adapted module-based TREATment mhGAP school program and investigate effective implementation strategies and client outcomes.,Intervention mapping to adapt the mhGAP-IG to a primary school setting, and implementation mapping to develop implementation strategies with user involvement,The main objective of the TREAT INTERACT study is to adapt, implement and evaluate the impact of an adapted school version of the mhGAP-IG that aims to prevent, identify, refer and treat mental health problems in children and adolescents in Uganda through a user involved task-shifting implementation of the mhGAP-IG among primary school staff. This work is divided into 4 work Packages (WPs); each of the specific objectives below represents a single work package.,
|
Mbale, Primary schools
|
Uganda |
2024-02-02 12:05:35 |
2027-02-02 |
612 teachers |
Teachers and pupils at primary schools |
Norwegian research Council |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Andrew Odur
ID: UNCST-2022-R009128
|
A RANDOMIZED CONTROL TRIAL TO DETERMINE THE EFFICACY OF MACHINE LEARNING MODELS TO PREDICT POSTPARTUM HEMORRHAGE
REFNo: HS3132ES
Determine whether earlier knowledge of the high-risk patient likelihood of morbidity can change clinical management to better outcomes,Demonstrate the efficacy of a mobile app prediction-based platform in informing clinical judgment,Determine the suitability of mobile app-based platform integration into the clinical workflow of African obstetricians,Determine the efficacy of ML models to predict the likelihood of pregnancy complications among African mothers,We aim to conduct a randomized control trial to determine the efficacy of machine learning models to predict postpartum hemorrhage to potentially establish a new gold standard way of screening patients in low-resource settings,
|
Lira, Cathedral
|
Uganda |
2023-10-02 15:32:14 |
2026-10-02 |
RCT sample size will be 200 |
The study will enroll pregnant women 18 years and older attending ANC at Lira Regional Referral Hospital intending to deliver from the same facility residing within 10 km distance from the hospital. |
INFIUSS Health, Inc |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Nixon Niyonzima
ID: UNCST-2020-R014577
|
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB IN COMBINATION WITH PHESGO→ VERSUS PLACEBO IN COMBINATION WITH PHESGO→ AS MAINTENANCE THERAPY AFTER FIRST LINE INDUCTION THERAPY IN PARTICIPANTS WITH PIK3CA‑MUTATED HER2‑POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (INAVO122)
REFNo: HS5649ES
This study will enrol particpants
|
Kampala, Mulago
|
Uganda |
2025-03-07 18:26:49 |
2028-03-07 |
20 |
Adult females above 18 years of age with breast cancer |
F.Hoffman La Roche |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Prudence Beinamaryo
ID: UNCST-2023-R007239
|
Efficacy of the combination ivermectin and albendazole vs albendazole alone in school-aged children infected with Trichuris trichiura: a randomized controlled trial
REFNo: HS3160ES
To evaluate the safety and tolerability of the ,To determine the CRs and ERRs of the study drugs (i.e. albendazole alone, albendazole-ivermectin) against Ascaris lumbricoides and hookworm in co-infected participants.,To determine the egg reduction rates (ERRs) of ivermectin/albendazole combination therapy compared to albendazole monotherapy against T. trichiura,To demonstrate that co-administered ivermectin (200 µg/kg) plus albendazole (400 mg) is superior to albendazole (400 mg) monotherapy in terms of CRs against T. trichiura infections assessed by Kato-Katz at 14-21 days post-treatment in individuals aged 6-12 years.,
|
Kabale, Rukore
Kabale, Rukore
|
Uganda |
2023-10-04 13:42:09 |
2026-10-04 |
750 |
School age children of from Age 6-12 both males and female of any tribe residing in area. |
Prof. Dr. Jennifer Keiser |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
JOSAPHAT KAYOGOZA BYAMUGISHA
ID: UNCST-2019-R001680
|
A phase II/III, open-label, randomized clinical trial to evaluate the efficacy and safety of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in life-threatening postpartum haemorrhage (PPH) in reducing adverse maternal outcome compared to standard of care in Uganda.
REFNo: HS3240ES
To assess the time to insert the REBOA.,To assess if the proportion of participants with either maternal death and/or emergency hysterectomy is lower in the intervention arm when excluding ‘inevitable’ hysterectomies due to either an irreparable uterine rupture, a pathological placenta growing into the uterus (placenta accreta, increta or percreta) or a pathological uterus, such as a bicorne uterus or one with very large fibroids.,To assess if post-partum haemoglobin concentration is higher in in the intervention arm compared to the comparator arm,To assess if the number of blood transfusion units is lower in the intervention arm compared to the comparator arm.,To assess if the number of participants with acute kidney injury is lower in the intervention arm compared to the comparator arm,To assess if the proportion of participants with maternal deaths is lower in the intervention arm compared to the comparator arm.,To assess if the proportion of participants with emergency hysterectomy, is lower in the intervention arm compared to the comparator arm., To assess the safety of REBOA in a national referral hospital in a low-income country like Uganda.,To assess if the proportion of participants with either maternal death and/or emergency hysterectomy, can be decreased from 50 % in the comparator arm (using standard of care alone) to 30 % or less in the intervention arm (using REBOA). ,
|
Kampala, Kawempe
|
Uganda |
2023-11-13 12:15:41 |
2026-11-13 |
10 women in phase IIb and 212 women in Phase III (222 IN TOTAL) |
Women aged 18 and above years and emancipated minors with life-threatening PPH and a systolic blood pressure equal to or less than 80 mmHg will be recruited |
Centre For International Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Esther Atukunda Cathyln
ID: UNCST-2019-R001701
|
Integration of a patient-centered mobile health intervention (Support-Moms) into routine antenatal care to improve maternal health in Uganda.
REFNo: HS3366ES
Evaluate the cost and cost-effectiveness of implementing Support-Moms intervention into routine care and implications for sustainability,Evaluate intervention implementation using the Proctor framework and plan for future scale-up per the Consolidated Framework for Implementation Research ,Test the effectiveness of the Support-Moms intervention in a randomized controlled trial,
|
|
Uganda |
2023-11-13 12:57:49 |
2026-11-13 |
824 |
We will include individuals who: 1) are in the first trimester of pregnancy who have not yet presented for ANC, 2) reside in the catchment area of a study HC, 3) are emancipated minors and adults aged ≥ 18 years, 4) report access to a cell phone with reception in their home, 5) are able to identify at least two social supporters living within the study districts, and 6) are able to provide consent. |
National Institutes of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
sunday anziku oyeeson
ID:
|
Exploring the Teachers’ Feedback Practices and its Influence on Students’ Learning in CBC: A case of a selected secondary school in Central Division, Arua City.
REFNo: SS2007ES
To explore how teachers’ feedback influences students' learning in CBC in lower secondary schools in Arua City.
To find out how students perceive the influence of feedback on their own learning in CBC.
To examine the strategies used by teachers to administer feedback to students in CBC in lower secondary schools in Arua City.
To find out the challenges faced by teachers in administering feedback to students in CBC in lower secondary schools in Arua City.
|
|
Uganda |
2023-11-16 13:34:21 |
2026-11-16 |
2 school administrators (Headteacher and Deputy), 3 Teachers of lower secondary or CBC classes (S.1, S.2, and S.3) and 9 Students in CBC classes (considering 3 students from each class) |
The study will be conducted in a secondary school involving CBC class students, teachers and the school administrators |
Self-Sponsored |
Social Science and Humanities |
Clinical Trial |
Degree Award |
|
Ahmed Ddungu
ID: UNCST-2019-R000944
|
CHARACTERIZATION OF TUBERCULOSIS ASSOCIATED LUNG FIBROSIS AND RESPIRATORY IMPAIRMENT, AND PREVENTION USING DOXYCYCLINE IN A DOUBLE BLIND RANDOMISED CONTROLLED TRIAL
REFNo: HS3385ES
To characterise/describe TB associated lung fibrosis and TB associated chronic respiratory impairment (where appropriate: burden and severity, radiological phenotype based on high resolution CT, clinical phenotype based on symptoms and lung function status, and predictors/ associations (including with selected biomarkers)); and to assess the efficacy of doxycycline as an adjuvant therapy to prevent TALF amongst patients with advanced TB
|
Kampala, Mulago
|
Uganda |
2024-03-20 15:59:56 |
2027-03-20 |
0200 |
- Age of 18 – 65 years
- sex : Male and Female
- Tribe (Non discriminatory of tribe)
- Index PTB episode (sputum smear positive or GeneXpert positive with rifampicin susceptibility)
- Baseline Chest X-ray showing infiltrates in at least 2 lung zones (≥30% lung involvement) meeting criteria for moderate/advanced PTB
- HIV uninfected (clinical trial )
- Subjects willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Able to give written informed consent. |
Makerere University Research and innovation Fund and Makerere University Lung Institute through the MAKNCD PROGRAM |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Jude Byansi Zziwa
ID:
|
DEVELOPING A FRAMEWORK FOR PROVIDING SUSTAINABLE SANITATION SERVICES IN URBAN SCHOOLS IN LOW- AND MIDDLE-INCOME COUNTRIES: A CASE OF TWO CITIES IN UGANDA
REFNo: SIR254ES
(iv) To establish the effect of the school centered sanitation service framework on human faecal exposure pathways in urban schools of LMICs.,To ascertain how the key factors in objective (ii) above, interact to provide sustainable sanitation services in city schools,To establish factors sustaining sanitation service provision in city schools,To determine the status of sanitation service provision in city schools ,The general objective of this study is to develop a sanitation management framework that will contribute to sustainable service provision in urban schools of Low- and Middle Income Countries (LMICs).,
|
Arua, Pajuni, Adumi, Oluko, Todamu, Aroi, Manibe and Ayivuni
Arua, Arua Hill, River Oli
Arua, Pajuni, Adumi, Oluko, Todamu, Aroi, Manibe and Ayivuni
Arua, Arua Hill, River Oli
|
Uganda |
2023-11-20 15:27:51 |
2026-11-20 |
2,434 participants |
The pupil population from age 9 to 25 years, Teacher population from age 23 to 60 years, Other stakeholders will be adults. Male and female participants will be balanced. |
Citywide Inclusive sanitation Program |
Engineering and Technology |
Clinical Trial |
Degree Award |
.jpg)
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
SOLIDARITY TRIAL-A phase I/II Randomized Placebo controlled trial to evaluate the Safety and Immunogenicity of Sudan Ebolavirus in Uganda
REFNo: HS3190ES
Phase I (rVSV-SUDV)
1. To determine the safety of rVSV-SUDV candidate SUDV vaccine among adult healthy volunteers in Uganda.
2. To determine the immunogenicity of rVSV-SUDV candidate SUDV vaccine.
Phase II (ChAdox1, CAd3 and rVSV-SUDV)
Primary objectives
1. To determine the safety of ChAdox1, CAd3 and rVSV-SUDV candidate SUDV vaccines among healthy volunteers and persons with stable comorbidities.
2. To determine the immunogenicity of ChAdox1, CAd3 and rVSV-SUDV candidate SUDV vaccines.
Secondary objectives
1. To determine the durability of SUDV-specific induced immune responses following vaccination.
2. To determine the factors associated with optimal vaccine-induced immune responses.
3. To determine the putative cross reactivity by the SUDV vaccine candidates against other ebolaviruses (e.g. Bundibugyo ebolavirus (BUDV) and EBOV).
Exploratory objectives
1. To determine the effect of SUDV vaccines on host gene expression.
2. To determine the T and B cell specific responses and immune profiling in response to vaccination.
3. To determine the effect of SUDV vaccines on the host metabolome.
4. To determine the effect of SUDV vaccines on host innate immune responses.
|
Kabarole, Fort portal
Kampala, Mulago I
Kayunga, Kayunga
Mbarara, Rubindi
Wakiso, Nkumba
Mubende, Kikanddwa
Masaka, Kabonera
|
Uganda |
2024-02-26 13:31:25 |
2027-02-26 |
2121 participants will be recruited in phase II and phase I will recruit 250 participants |
healthy volunteers both male and females will be recruited in the study regardless of the ethnic group they belong to. The participants will recruit people aged 6-65 in to phase I and phase to |
World Health Organization and Ministry of Health Uganda |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
.jpg)
|
alfred bulamu
ID: UNCST-2023-R008638
|
Uganda Translational Breast Cancer Screening Research Center with Innovations in MRI and Genetic Testing.
REFNo: HS4689ES
Implementation of breast MRI with genetic testing as BC screening method for women at high risk of BC by July 2029 (Phase 6) , Continuous Trainings for radiologists, radiographers and laboratory staffs on the modern technologies of MRI and Genetic testing (phase 3 to phase 6) ,Evaluating the feasibility of screening BC using MRI and genetic testing for high risk women by December 2028 (phase 5),Large scale education of the community about BC by July 2028 (phase 3 and phase 4).,Large scale determination of the utility of genetic testing as a screening modality for BC in Uganda by perform mutational genetic analysis for women at high-risk aged19 years to 80 years by July 2028 (phase 3 and phase 4) , Large scale determination of the utility of quantitative breast MRI for screening women at high risk BC aged 19 years to 80 years by July 2028 (phase 3 and phase 4) ,Training of the users on equipment i.e. Radiologists, Radiographers and laboratory staffs by 2025 (phase 2) ,Securing and installation of lab equipment for genetic testing by 2025 (Phase 2,Securing and installation of MRI with Breast coils by July 2025 (Phase 2),To build capacity for 20 laboratory health care workers in genetic testing technologies by December 2023 (phase 1).,To build capacity for 30 radiology health professionals in modern breast Imaging with MRI by December 2023 (Phase 1),To determine the utility of quantitative breast MRI for screening women at high risk breast cancer aged 19 years to 80 years by July 2024 (phase 1),To determine the utility of genetic testing as a screening modality for BC in Uganda by perform mutational genetic analysis for women at high-risk of BC aged 19 years to 80 years, by July 2024 (phase1),To build a long-lasting infrastructure for research, clinical screening in Uganda and training using modern technologies. ,To offer improved access to Breast Cancer screening in Uganda through quantitative MRI and genetic testing research center,
|
All Districts, All parishes
|
Uganda |
2024-08-06 17:27:31 |
2027-08-06 |
100 participants |
All women at the risk of breast Cancer between the Ge of 19 year to 80years of all the tribes in the different regions |
Kiphart Foundation |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Betty Mwesigwa
ID: UNCST-2020-R014667
|
Sabin 003: A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to
Evaluate Safety, Tolerability, and Immune Responses of an
Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan
Ebolavirus Vaccine in Healthy Adults
REFNo: HS3628ES
To evaluate the safety and tolerability of cAd3-EBO S vaccine
|
Kampala, Central
Kampala, Central
Kampala, Central
|
Uganda |
2024-02-13 17:35:43 |
2027-02-13 |
125 participants |
18 to 70-year old healthy adults |
Sabin Vaccine Institute |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Dennis Ssesanga Ernest
ID: UNCST-2023-R008022
|
EFFECT OF MHEALTH COMMUNICATION ON STIGMA AND RETENTION IN CARE AMONG YOUTH LIVING WITH HIV AND LINKED TO CARE IN UGANDA.
REFNo: SS2215ES
1. To explore the effect of mhealth communication on stigma among youth living with HIV and linked to care in Uganda.
2. To systematically develop and evaluate an mHealth intervention on stigma and retention in care among youth living with HIV and linked to care in Uganda.
3. To investigate the determinants of stigma and retention in care among youth living with HIV and linked to care in Uganda.
4. To determine the effect of mhealth communication on retention in care among youth living with HIV and linked to care in Uganda.
|
Kampala, Nsambya
Kampala, Mulago
Jinja,
Jinja,
|
Uganda |
2023-12-19 11:26:33 |
2026-12-19 |
142 |
Participants will include voluntary consented and assented HIV-positive patients aged 15-24 years, who communicate in English, Lusoga or Luganda. Clinical |
Uganda Virus Research Institute |
Social Science and Humanities |
Clinical Trial |
Degree Award |
|
Fred Ssewamala
ID: UNCST-2020-R014060
|
Bridges2Scale: Testing Implementation Strategies for an intervention among young people affected by AIDS
REFNo: SS2488ES
Bridges2Scale will use a two-arm Hybrid III effectiveness-implementation cluster randomized clinical trial, where we will compare two multifaceted strategies (standard vs. enhanced) for scaling the Bridges interventions (consisting of financial literacy training, peer mentorship, family income-generating , and youth development accounts). The standard implementation strategy has been applied in our prior and ongoing studies and involves educational meetings that prepare staff members to deliver Bridges with minimal disruption to site workflow. This will be compared to an enhanced strategy that will be developed using Implementation Mapping, a systematic protocol for developing implementation strategies using theory, evidence, and stakeholder input.
Aim 1: Compare the implementation effectiveness of the standard implementation strategy vs. an enhanced implementation strategy.
Aim 2: Determine the clinical effectiveness of Bridges implemented via a standard vs. enhanced implementation strategy.
Aim 3: Explore implementation processes, mechanisms, and determinants.
Aim 4: Compare the cost and cost-effectiveness of the two implementation strategies.
|
Masaka, Kimaanya
Rakai, Kakuuto
Kyotera, Kyotera TC
Lwengo, Lwengo
Kalungu, Kasaali
Sembabule, Parish ward
Bukomansimbi, Mbiriizi
|
Uganda |
2024-04-19 18:42:54 |
2027-04-19 |
1440 |
Inclusion and Exclusion Criteria:
Adolescent Inclusion Criteria: (1) ages 13-17 years; (2) a student at one of the 48 public primary schools included in the study; (3) living within a family and not an institution/orphanage.
Caregiver Inclusion Criteria: A caregiver would be eligible if they are (1) self-identified and confirmed by the AY as primary caregiver of the AY; and (2) capable of providing informed consent.
Schools’ inclusion criteria: The 48 public (government) primary schools would be eligible if they are (1) located in one of the seven districts in the greater Masaka region – on secondment from the Ministry of Education or local government representative (District Education Officer [DEO]), and (2) willing and able to participate in study implementation.
Youth-serving NGOs will be invited if they are: (1) registered with the government of Uganda; (2) willing to work with the study team; and (3) have a history of implementing micro-finance EE interventions.
Exclusion criteria: Adolescents will be ineligible if: 1) they are unable to understand study procedures and participant rights as assessed during informed consent/assent process with the adolescent and parent. 2) If the adolescent or adult caregiver presents with emergency needs (e.g., hospitalization), needed care will be secured, rather than study participation.
Facilitator Recruitment. The leaders of public schools and youth-serving NGOs will help us select the facilitators based on their interest in the intervention and willingness to work with study participants.
Standard Implementation Strategy (SIS) condition. we will meet with both NGO and school staff to gauge their interest in partnering on study implementation and describe roles and responsibilities.
Enhanced Implementation Strategy (EIS) condition. The headmaster of each school in the EIS will identify at least 2 teachers per school to be enrolled in the study and deliver the intervention—as implementation champions. We expect to recruit at least 48 teachers in EIS (2 teachers/school x 24 schools). Similar procedures will be followed for NGO staff. Specifically, we will recruit at least 8 facilitators from NGOs and 8 facilitators from community (including PTA members) to serve as trainers for implementation champions.
|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Sam Ononge
ID: UNCST-2020-R000328
|
A CLINICAL TRIAL TO EVALUATE THE PERFORMANCE AND SAFETY OFTHE WEKEBERE SYSTEM FOR MONITORING FETAL WELLBEING DURING LABOUR
REFNo: HS3407ES
The overall objective of this study is to demonstrate safety and performance of wekebere fetal monitoring system.
Specific Objectives
To determine accuracy of wekebere fetal monitoring in comparison with gold standard. To determine the safety of wekebere system
To determine’ uterine contractions
|
Kampala, Kawempe
|
Uganda |
2025-06-30 9:35:11 |
2028-06-30 |
120 |
The study population will consist of the following inclusion criteria: i.Female age between: 18-50
ii.Gestational age >36 + 0 weeks iii.Singleton pregnancy
iv.Early labor (cervical dilatation of <6cm)
v.Sign informed consent |
Villgro Africa |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Zubair Lukyamuzi
ID: UNCST-2021-R013107
|
Feasibility and Acceptability of a Barbershop Based HIV Prevention Initiative Among Heterosexual Men in Kalangala Islands, Uganda: A Cluster Randomized Trial
REFNo: HS3430ES
1. To compare completion of self-initiated HIV testing between intervention and control groups
2. To evaluate the preliminary effectiveness of the intervention on change in behaviors associated with HIV acquisition
3. To compare interest in or use of HIV prevention services between intervention and control groups
4. To evaluate the preliminary effectiveness of the intervention on incident STIs
|
Kalangala, Bugala Island
|
Uganda |
2024-01-08 13:20:21 |
2027-01-08 |
up 250 |
the study population will be men aged at least 16 at risk of HIV in Kalangala |
Division of AIDS (DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), US National Institutes of Health (NIH) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Kamoga Ronald
ID: UNCST-2019-R001524
|
VAGUS NERVE STIMULATION IN A RAT MODEL OF ALZHEIMER’S DISEASE-LIKE SYMPTOMS: MORPHOLOGICAL, IMMUNOHISTOCHEMICAL, MOLECULAR AND BEHAVIORAL CHANGES
REFNo: HS3781ES
1. To conduct a scoping review of literature on vagus nerve stimulation in Alzheimer's-disease and related dementias.
2. To determine behavioral changes associated with vagus nerve stimulation in a rat model of Alzheimer-like symptoms.
3. To evaluate the morphological, Immunohistochemical and molecular changes in the Hippocampus, prefrontal cortex and medial temporal cortex associated with chronic stimulation of the vagus nerve in a rat model of Alzheimer’s-like disease.
|
Mbarara, Medical cell
|
Uganda |
2024-02-26 13:43:22 |
2027-02-26 |
42 Wistar rats |
Wistar rats bewteen 3 months and 7 months old |
Self sponsorship |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
